Cargando…

The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance

Tyrosine kinase inhibitors (TKIs) are important in managing lymphoid malignancies by targeting B-cell receptor signaling pathways. Entospletinib (GS-9973) is an oral, selective inhibitor of spleen tyrosine kinase (Syk), currently in the phase II clinical trials for the treatment of chronic lymphocyt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Narayanan, Silpa, Wu, Zhuo-Xun, Wang, Jing-Quan, Ma, Hansu, Acharekar, Nikita, Koya, Jagadish, Yoganathan, Sabesan, Fang, Shuo, Chen, Zhe-Sheng, Pan, Yihang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315011/ https://www.ncbi.nlm.nih.gov/pubmed/34326700 http://dx.doi.org/10.7150/ijbs.61229

Ejemplares similares

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma
por: Burke, John M., et al.
Publicado: (2018)

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor
por: Burke, Russell T, et al.
Publicado: (2014)

MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study
por: Wu, Zhuo-Xun, et al.
Publicado: (2022)

Ellagic Acid and Schisandrins: Natural Biaryl Polyphenols with Therapeutic Potential to Overcome Multidrug Resistance in Cancer
por: Yoganathan, Sabesan, et al.
Publicado: (2021)

Anticancer effect of Indanone-based thiazolyl hydrazone derivative on p53 mutant colorectal cancer cell lines: An in vitro and in vivo study
por: Narayanan, Silpa, et al.
Publicado: (2022)

The Novel benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter
por: Narayanan, Silpa, et al.
Publicado: (2021)

Ciprofloxacin Enhances the Chemosensitivity of Cancer Cells to ABCB1 Substrates
por: Gupta, Pranav, et al.
Publicado: (2019)

Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib
por: Sender, Sina, et al.
Publicado: (2021)

Imperatorin Restores Chemosensitivity of Multidrug-Resistant Cancer Cells by Antagonizing ABCG2-Mediated Drug Transport
por: Wu, Chung-Pu, et al.
Publicado: (2023)

Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib
por: Sharman, Jeff, et al.
Publicado: (2016)

Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies
por: Kittai, Adam S., et al.
Publicado: (2021)

Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia
por: Loftus, Joseph P., et al.
Publicado: (2020)

An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma
por: Andorsky, David J., et al.
Publicado: (2018)

Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma
por: Morschhauser, Franck, et al.
Publicado: (2020)

Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor
por: Wu, Zhuo-Xun, et al.
Publicado: (2021)

N,N-dimethylacetamide targets neuroinflammation in Alzheimer’s disease in in-vitro and ex-vivo models
por: Wei, Zeng-Hui, et al.
Publicado: (2023)

Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers
por: Ramanathan, Srini, et al.
Publicado: (2016)

An efficient one-pot conversion of carboxylic acids into benzimidazoles via an HBTU-promoted methodology
por: Barasa, Leonard, et al.
Publicado: (2018)

Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside
por: Wu, Jingjing, et al.
Publicado: (2016)

VKNG-1 Antagonizes ABCG2-Mediated Multidrug Resistance via p-AKT and Bcl-2 Pathway in Colon Cancer: In Vitro and In Vivo Study
por: Narayanan, Silpa, et al.
Publicado: (2021)

Role of spleen tyrosine kinase in liver diseases
por: Kurniawan, Dhadhang Wahyu, et al.
Publicado: (2020)

The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions
por: Bhullar, Jasjeet, et al.
Publicado: (2013)

Targeting Spleen Tyrosine Kinase-Bruton's Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis
por: Chen, Jin-Shuen, et al.
Publicado: (2014)

Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2
por: Wang, De-Shen, et al.
Publicado: (2014)

Relative roles of ABCG5/ABCG8 in liver and intestine
por: Wang, Jin, et al.
Publicado: (2015)

Functional Cooperativity between ABCG4 and ABCG1 Isoforms
por: Hegyi, Zoltán, et al.
Publicado: (2016)

ABCG5 and ABCG8 Are Involved in Vitamin K Transport
por: Matsuo, Michinori, et al.
Publicado: (2023)

Behind the scenes of GS: preventing and curing - the GS-SE group
por: CERN, GS-SE
Publicado: (2013)

Spleen Tyrosine Kinase Inhibition Modulates p53 Activity
por: Althubiti, Mohammad
Publicado: (2017)

An inhibitor of spleen tyrosine kinase suppresses experimental crescentic glomerulonephritis
por: Han, Yingjie, et al.
Publicado: (2018)

Prognostic value of spleen tyrosine kinase in human solid tumors
por: Ni, Beibei, et al.
Publicado: (2018)

Alzheimer’s disease pathological lesions activate the spleen tyrosine kinase
por: Schweig, Jonas Elias, et al.
Publicado: (2017)

Sitosterolemia: Twenty Years of Discovery of the Function of ABCG5 ABCG8
por: Williams, Kori, et al.
Publicado: (2021)

Impact of Q141K on the Transport of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by ABCG2
por: Inoue, Yutaka, et al.
Publicado: (2019)

Autophagy Blockade by Ai Du Qing Formula Promotes Chemosensitivity of Breast Cancer Stem Cells Via GRP78/β-Catenin/ABCG2 Axis
por: Liao, Mianmian, et al.
Publicado: (2021)

Functional relationship of AtABCG21 and AtABCG22 in stomatal regulation
por: Kuromori, Takashi, et al.
Publicado: (2017)

Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells
por: Wu, Chung-Pu, et al.
Publicado: (2023)

Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases
por: Pamuk, Omer N, et al.
Publicado: (2010)

Spleen Tyrosine Kinase Mediates Microglial Activation in Mice With Diabetic Retinopathy
por: Liu, Xiaozhe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ok72p0aoqto1l3jop8v187on2k